Regulatory assessment: no numerical ADI set because long-term data are thin
When EFSA re-evaluated E163 anthocyanins in 2013, its experts concluded the available toxicological database was not adequate to establish a numerical acceptable daily intake. Long-term studies on chronic toxicity, carcinogenicity, and reproductive effects were described as extremely limited. The panel noted that at current food-use levels, exposure from grape skin and blackcurrant extracts is not expected to pose a concern, but called for better characterisation and toxicological data to support a future re-evaluation. No ADI has since been set.
EFSA concluded the toxicological database for anthocyanins (E163) was inadequate to establish a numerical ADI; long-term chronic toxicity, carcinogenicity, and reproductive studies were extremely limited.
2013Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal 2013;11(4):3145
Exposure from current use levels of aqueous grape skin extract and blackcurrant extract was not considered of safety concern, provided additive exposure was comparable to dietary intake of anthocyanins from fruit and vegetables.
2013Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), EFSA Journal 2013;11(4):3145
Antioxidant and anti-inflammatory activity in laboratory studies
Cell and test-tube studies show that malvidin glycosides reduce markers of inflammation in human endothelial cells and lower measures of oxidative stress. In one cell study, malvidin-3-glucoside suppressed inflammatory adhesion proteins by up to around 90% at high concentrations. These are laboratory findings, and whether the amounts of malvidin that actually reach human tissues after eating are sufficient to produce similar effects in the body is not established.
Malvidin-3-glucoside and malvidin-3-galactoside inhibited TNF-alpha-induced inflammatory adhesion molecules (ICAM-1, VCAM-1, MCP-1) in human umbilical vein endothelial cells in a dose-dependent manner.
2014LabHuang et al., Molecules, PMC6271830
Malvidin and its glycosides demonstrated antioxidant and anti-inflammatory effects across multiple cell and animal studies, primarily attributed to modulation of NF-kappaB signalling and free-radical scavenging.
2023Lab + animalLatorres et al., Nutrients 2023;15(13):3016 (MDPI), PMC identifier 37447342
Cardiovascular signals from blueberry trials, but evidence is moderate quality
Randomised trials of whole blueberries, which are among the richest food sources of malvidin, show modest improvements in measures of blood vessel function. A 2024 meta-analysis of 11 trials found that blueberry intake improved flow-mediated dilation by around 1.5 percentage points, with moderate-quality evidence. The effect is attributed to the mixed anthocyanin content of blueberries rather than malvidin alone, and results show high variability between studies.
A meta-analysis of 11 randomised trials (400 participants) found blueberry intake improved flow-mediated dilation by 1.50% (95% CI: 0.81, 2.20; I-squared = 87%), rated as moderate-quality evidence.
2024Meta-analysisFrontiers in Physiology, meta-analysis, doi: 10.3389/fphys.2024.1368892
Potential anti-cancer signals in lab and animal studies, no human trial evidence
Laboratory and animal studies show malvidin can reduce cell proliferation and promote cell death in several cancer cell lines, including leukemia, colon, gastric, liver, and breast models. Researchers have not yet run controlled human trials to test whether malvidin has any effect on cancer risk or progression in people. These findings describe what happens in cultured cells or rodents, not what happens in someone who eats malvidin-containing food.
In vitro and animal studies show malvidin reduces cell proliferation, promotes apoptosis, and suppresses metastasis in cancer cell lines including leukemia, colorectal, gastric, liver, lung, and breast models.
2024Lab + animalRoriz et al., Journal of Functional Foods 2024 (ScienceDirect S1756464624001932)
Authors noted that human clinical trials evaluating anticancer effects of malvidin are absent and called the compound's clinical translation at an early stage.
2024Lab + animalRoriz et al., Journal of Functional Foods 2024 (ScienceDirect S1756464624001932)
Low bioavailability: most reaches the colon, not the bloodstream
Human studies show anthocyanins including malvidin are poorly absorbed. After consuming red wine containing malvidin-3-glucoside, plasma concentrations peaked at around 1 to 2 nanomolar within 20 minutes, which is very low. Most of what is eaten passes to the large intestine where gut bacteria convert it into smaller phenolic acids such as syringic acid, which are then absorbed. Whether these breakdown products contribute to any health effects is an active research question.
After ingesting red wine providing 68mg malvidin-3-glucoside, plasma concentration peaked at approximately 1.38 nM at 20 minutes, indicating very low bioavailability.
2001ObservationalBub et al., European Journal of Nutrition 2001, PMID 11697443
Malvidin-3-glucoside is rapidly metabolised by colonic bacteria primarily to syringic acid, which is subsequently converted to gallic acid and protocatechuic acid; absorbed intact anthocyanin concentrations remain very low.
2012LabGonzalez-Barrio et al., Journal of Agricultural and Food Chemistry 2012, doi: 10.1021/jf3002153
